Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy
Anticancer Research · 2025
DOI: 10.21873/anticanres.17648 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Guidong Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The First Affiliated Hospital of Harbin Medical University, Harbin, P.R. China azumatakafumi@163.com. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Methotrexate, Osteosarcoma, Bone Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The First Affiliated Hospital of Harbin Medical University, Harbin, P.R. China azumatakafumi@163.com.
- Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
- Department of Orthopedics, Uonuma Kikan Hospital, Niigata, Japan.
Zitieren
APA
Li, G., Kawashima, H., Sasaki, T., Ariizumi, T., Oike, N., & Ogose, A. (2025). Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy. Anticancer Research. https://doi.org/10.21873/anticanres.17648
Vancouver
Li G, Kawashima H, Sasaki T, Ariizumi T, Oike N, Ogose A. Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy. Anticancer Research. 2025. doi:10.21873/anticanres.17648
BibTeX
@article{Li2025,
author = {Li, Guidong and Kawashima, Hiroyuki and Sasaki, Taro and Ariizumi, Takashi and Oike, Naoki and Ogose, Akira},
title = {Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17648}
}
EUVIMED